Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

ASCO 2015 | Results of the ENDEAVOR trial comparing carfilzomib and bortezomib in multiple myeloma

Joseph Mikhael • 2 Jun 2015
ASCO 2015
Multiple Myeloma Bortezomib Carfilzomib

Dr Joseph Mikhael discusses the results of the ENDEAVOR trial, a phase 3 head-to-head study that demonstrates superiority of carfilzomib over bortezomib in patients with relapsed multiple myeloma.

More from Joseph Mikhael

Bridging the gap in myeloma care: ensuring access for all patients 1:55
Bridging the gap in myeloma care: ensuring access for all patients
Joseph Mikhael • 5 Sep 2025
Areas of consensus and controversy in the current and future management of R/R multiple myeloma 2:36
Areas of consensus and controversy in the current and future management of R/R multiple myeloma
Joseph Mikhael • 5 Sep 2025
The benefits of telehealth in promoting equity in blood cancer care 2:11
The benefits of telehealth in promoting equity in blood cancer care
Joseph Mikhael • 5 Sep 2025
The importance of shared decision-making & patient preferences in myeloma care 1:56
The importance of shared decision-making & patient preferences in myeloma care
Joseph Mikhael • 5 Sep 2025

Related Videos

The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial 10:22
The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial
Peter Voorhees • 19 Nov 2025
Promising approaches being explored in high-risk myeloma & trials to look out for 2:11
Promising approaches being explored in high-risk myeloma & trials to look out for
Sham Mailankody • 24 Oct 2025
The value of extensive profiling in single-arm trials for high-risk myeloma 2:39
The value of extensive profiling in single-arm trials for high-risk myeloma
Martin Kaiser • 24 Oct 2025
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy? 2:35
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy?
Sham Mailankody • 24 Oct 2025
The content of VJHemOnc is intended for healthcare professionals